Mirati Therapeutics, Inc.

NasdaqGS:MRTX 株式レポート

時価総額：US$4.1b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Mirati Therapeutics マネジメント

マネジメント 基準チェック /44

Mirati Therapeutics'の CEO はChuck Baumで、 Nov2012年に任命され、 の在任期間は 11.17年です。 の年間総報酬は$ 7.42Mで、 9.2%給与と90.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.16%を直接所有しており、その価値は$ 6.57M 。経営陣と取締役会の平均在任期間はそれぞれ2.5年と5.1年です。

主要情報

Chuck Baum

最高経営責任者

US$7.4m

報酬総額

CEO給与比率9.2%
CEO在任期間11.2yrs
CEOの所有権0.2%
経営陣の平均在職期間2.5yrs
取締役会の平均在任期間5.1yrs

経営陣の近況

Recent updates

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Oct 05
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Jun 22
Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

May 17
Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Feb 01
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

Dec 09
Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Oct 08
We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Sep 11
Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Mirati: A Potential Blockbuster Stock, Will Need Patience

Sep 08

Mirati jumps 11% as Amgen meets key goal for rival cancer drug

Aug 31

Mirati gains as Amgen posts new combination data for rival cancer drug

Aug 08

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Aug 08
Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Jun 21

CEO報酬分析

Mirati Therapeutics の収益と比較して、Chuck Baum の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2023n/an/a

-US$726m

Jun 30 2023n/an/a

-US$738m

Mar 31 2023n/an/a

-US$737m

Dec 31 2022US$7mUS$685k

-US$741m

Sep 30 2022n/an/a

-US$738m

Jun 30 2022n/an/a

-US$645m

Mar 31 2022n/an/a

-US$634m

Dec 31 2021US$18mUS$662k

-US$582m

Sep 30 2021n/an/a

-US$483m

Jun 30 2021n/an/a

-US$491m

Mar 31 2021n/an/a

-US$407m

Dec 31 2020US$12mUS$615k

-US$358m

Sep 30 2020n/an/a

-US$329m

Jun 30 2020n/an/a

-US$296m

Mar 31 2020n/an/a

-US$259m

Dec 31 2019US$8mUS$597k

-US$213m

Sep 30 2019n/an/a

-US$169m

Jun 30 2019n/an/a

-US$142m

Mar 31 2019n/an/a

-US$125m

Dec 31 2018US$5mUS$580k

-US$98m

Sep 30 2018n/an/a

-US$88m

Jun 30 2018n/an/a

-US$77m

Mar 31 2018n/an/a

-US$67m

Dec 31 2017US$2mUS$563k

-US$70m

報酬と市場: Chuckの 総報酬 ($USD 7.42M ) は、 US市場 ($USD 6.76M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Chuckの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Chuck Baum (65 yo)

11.2yrs

在職期間

US$7,420,213

報酬

Dr. Charles M. Baum, M.D., Ph D., also known as Chuck, is a Director of Acrivon Therapeutics, Inc. from June 2023. Dr. Baum is an Independent Director of Poseida Therapeutics, Inc. from May 16, 2022.He se...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Charles Baum
Founder11.2yrsUS$7.42m0.16%
$ 6.6m
James Christensen
Executive VP & Chief Scientific Officer10yrsUS$5.01m0.082%
$ 3.4m
Alan Bart Sandler
Executive VP & Chief Medical Officer1.2yrsUS$5.30m0.014%
$ 587.2k
Aaron Ondrey
Chief Financial Officerless than a yearデータなし0.056%
$ 2.3m
Betsy Gelfand
Chief Accounting Officerless than a yearデータなしデータなし
John Moriarty
Chief Legal Officer & Corporate Secretaryless than a yearデータなしデータなし
Peter Lee
Chief Compliance Officer2yrsデータなしデータなし
Michael Paolucci
Chief People Officer2yrsデータなしデータなし
Benjamin Hickey
Chief Commercial Officer4yrsUS$6.93m0.040%
$ 1.6m
Kelly Covello
VP & Head of Medical Affairs3.8yrsデータなしデータなし
Ryan Asay
VP & Head of Corporate Affairs3.8yrsデータなしデータなし
Susan Welsh
Senior VP of Pharmacovigilance & Chief Safety Officer3yrsデータなしデータなし

2.5yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: MRTXの経営陣は 経験豊富 であると考えられます ( 2.5年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Charles Baum
Founder11.2yrsUS$7.42m0.16%
$ 6.6m
Bruce Leonard Carter
Independent Director7.3yrsUS$700.41k0.0086%
$ 353.3k
George Demetri
Member of Scientific Advisory Boardno dataデータなしデータなし
Faheem Hasnain
Chairman & Lead Independent Director4.9yrsUS$979.79k0.012%
$ 511.8k
Julie Michele Cherrington
Independent Director4.6yrsUS$697.91k0%
$ 0
Stephen Baylin
Member of Scientific Advisory Boardno dataデータなしデータなし
Lillian Siu
Member of Scientific Advisory Boardno dataデータなしデータなし
Aaron Davis
Independent Director5.1yrsUS$677.91k0.061%
$ 2.5m
Pasi Antero Janne
Member of Scientific Advisory Board5yrsデータなしデータなし
Craig Johnson
Independent Director10.3yrsUS$702.91k0.0086%
$ 353.3k
Channing Der
Member of Scientific Advisory Board5yrsデータなしデータなし
Maria Martinez-Davis
Independent Director5.1yrsUS$695.41k0.0086%
$ 353.3k

5.1yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: MRTXの 取締役会 は 経験豊富 であると考えられます ( 5.1年の平均在任期間)。